Correlation Between Alnylam Pharmaceuticals and Agios Pharm

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Alnylam Pharmaceuticals and Agios Pharm at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Alnylam Pharmaceuticals and Agios Pharm into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Alnylam Pharmaceuticals and Agios Pharm, you can compare the effects of market volatilities on Alnylam Pharmaceuticals and Agios Pharm and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Alnylam Pharmaceuticals with a short position of Agios Pharm. Check out your portfolio center. Please also check ongoing floating volatility patterns of Alnylam Pharmaceuticals and Agios Pharm.

Diversification Opportunities for Alnylam Pharmaceuticals and Agios Pharm

-0.06
  Correlation Coefficient

Good diversification

The 3 months correlation between Alnylam and Agios is -0.06. Overlapping area represents the amount of risk that can be diversified away by holding Alnylam Pharmaceuticals and Agios Pharm in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Agios Pharm and Alnylam Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Alnylam Pharmaceuticals are associated (or correlated) with Agios Pharm. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Agios Pharm has no effect on the direction of Alnylam Pharmaceuticals i.e., Alnylam Pharmaceuticals and Agios Pharm go up and down completely randomly.

Pair Corralation between Alnylam Pharmaceuticals and Agios Pharm

Given the investment horizon of 90 days Alnylam Pharmaceuticals is expected to generate 1.18 times more return on investment than Agios Pharm. However, Alnylam Pharmaceuticals is 1.18 times more volatile than Agios Pharm. It trades about 0.08 of its potential returns per unit of risk. Agios Pharm is currently generating about -0.04 per unit of risk. If you would invest  23,601  in Alnylam Pharmaceuticals on December 28, 2024 and sell it today you would earn a total of  3,245  from holding Alnylam Pharmaceuticals or generate 13.75% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Alnylam Pharmaceuticals  vs.  Agios Pharm

 Performance 
       Timeline  
Alnylam Pharmaceuticals 

Risk-Adjusted Performance

OK

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Alnylam Pharmaceuticals are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Alnylam Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point.
Agios Pharm 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Agios Pharm has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unfluctuating performance, the Stock's forward indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors.

Alnylam Pharmaceuticals and Agios Pharm Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Alnylam Pharmaceuticals and Agios Pharm

The main advantage of trading using opposite Alnylam Pharmaceuticals and Agios Pharm positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Alnylam Pharmaceuticals position performs unexpectedly, Agios Pharm can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Agios Pharm will offset losses from the drop in Agios Pharm's long position.
The idea behind Alnylam Pharmaceuticals and Agios Pharm pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Other Complementary Tools

Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Equity Valuation
Check real value of public entities based on technical and fundamental data
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets